Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$244.1 million.

  • Ernexa Therapeutics' Retained Earnings fell 811.6% to -$244.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$244.1 million, marking a year-over-year decrease of 811.6%. This contributed to the annual value of -$231.5 million for FY2024, which is 2382.86% down from last year.
  • As of Q3 2025, Ernexa Therapeutics' Retained Earnings stood at -$244.1 million, which was down 811.6% from -$242.9 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Retained Earnings registered a high of -$55.1 million during Q1 2021, and its lowest value of -$244.1 million during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$178.0 million (2023), whereas its average is -$177.3 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' Retained Earnings surged by 5848.27% in 2021, and later crashed by 17249.75% in 2022.
  • Ernexa Therapeutics' Retained Earnings (Quarter) stood at -$151.2 million in 2021, then fell by 9.3% to -$165.3 million in 2022, then decreased by 13.12% to -$187.0 million in 2023, then dropped by 23.83% to -$231.5 million in 2024, then decreased by 5.44% to -$244.1 million in 2025.
  • Its Retained Earnings stands at -$244.1 million for Q3 2025, versus -$242.9 million for Q2 2025 and -$239.7 million for Q1 2025.